Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962802 | 0.90 | MAPT (0.45) | CDC7CDK2RAPGEF4MAPT | |
| SCHEMBL961623 | 0.83 | ALDH1A1 (0.47) | CDC7CDK2RAPGEF4TGFBR1MKNK2 | |
| SCHEMBL961622 | 0.83 | ALDH1A1 (0.47) | CDC7CDK2RAPGEF4TGFBR1MKNK2 | |
| SCHEMBL965856 | 0.83 | HTT (0.40) | CDC7CDK2SMN1; SMN2MAPT | |
| SCHEMBL961972 | 0.81 | ROCK1 (0.41) | SMN1; SMN2MAPTCYP2A6 | |
| SCHEMBL963262 | 0.80 | TBXAS1 (0.36) | CDC7CDK2RAPGEF4TGFBR1MKNK2 | |
| SCHEMBL963260 | 0.80 | TBXAS1 (0.36) | CDC7CDK2RAPGEF4TGFBR1MKNK2 | |
| SCHEMBL963258 | 0.79 | CCNC (0.47) | CDC7CDK2RAPGEF4TGFBR1MKNK2 | |
| SCHEMBL962714 | 0.79 | ALDH1A1 (0.38) | SMN1; SMN2MAPTCYP2A6 | |
| SCHEMBL963702 | 0.79 | SMN1; SMN2 (0.45) | CDK2SMN1; SMN2MAPTCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008110672-A1 | USE OF A C-GLYCOSIDE DERIVATIVE AS AN ANTI-OXIDANT AGENT | L'OREAL (FR) | 2008-09-18 | — | — | WO | claimed |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| CN-101646653-A | Fused ring compounds as partial agonists of ppar-gamma | TAKEDA PHARMACEUTICAL JP | 2010-02-10 | — | — | CN | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2043594-A2 | COSMETIC USE OF A C-GLYCOSIDE DERIVATIVE IN COMBINATION WITH ASCORBIC ACID | L'Oreal (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| WO-2008003900-A2 | COSMETIC USE OF A C-GLYCOSIDE DERIVATIVE IN COMBINATION WITH ASCORBIC ACID | L'OREAL (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | CDC7 2245/4885CDK2 2555/4885RAPGEF4 2802/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | CDC7 4163/4885CDK2 2985/4885RAPGEF4 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.